FDA Narrowly Votes in Favor of Pfizer RSV Vaccine

Despite some safety concerns, on Tuesday, February 28, vaccine advisers to the US Food and Drug Administration narrowly voted in favor of Pfizer’s RSV vaccine for adults over the age of 60, paving the way for approval of the first nation’s RSV vaccine.

The FDA is scheduled to decide on approval of the vaccines by May, ahead of RSV’s typical winter surge. The US Centers for Disease Control and Prevention must then recommend the shot before it becomes available to the public.

Get more details here.